Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."
from International: Top News And Analysis https://ift.tt/AnXYdCJ
via IFTTT
Ticker Tape by TradingView
Tuesday, June 27, 2023
Regeneron shares fall after FDA rejects high-dose eye disease treatment
Subscribe to:
Post Comments (Atom)
Ticker Tape by TradingView
No comments:
Post a Comment